Then there’s the Lundquist Institute, a nonprofit biomedical research organization in Los Angeles. The institute occupies six buildings on a campus spanning 11.5 acres and is usually bustling with over 750 full- and part-time employees.
These days? “It’s a ghost town,” said David Meyer, the institute’s CEO.
Two common hormone therapy regimens had opposite long-term effects on breast cancer incidence among postmenopausal women, according to results from two large randomized controlled Women’s Health Initiative trials presented at San Antonio Breast Cancer Symposium.
The showcase once again made the institute, on the Harbor-UCLA Medical Center campus, the center of the biomedical world in Southern California. It also gave the research center — located in an unincorporated part of Los Angeles County, east of Torrance — a chance to display its new 78,000-square-foot, 4-story medical research lab building, which opened in March.
Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. of Los Angeles announced today expansion into the life science incubator research lab facilities (Martin Laboratory Incubator) at LA BioMed with access privileges to BioLabs LA which is across the street.
Hormone replacement therapy is a common treatment for menopause-related symptoms, and new research from the University of Pittsburgh Graduate School of Public Health reinforces the importance of tailoring hormone therapy to each patient, based on her individual risk factors for cardiovascular disease.
[R]esearchers from the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center used coronary computed tomography angiography to determine whether the rate of coronary plaque progression differs in people with vs without diabetes.
Melanie Lundquist is a leading philanthropist who focuses her support on various healthcare and education initiatives. Lundquist is at the forefront of philanthropic efforts to improve the lives of her fellow Angelenos by driving systemic change.
On March 25 of this year, researchers of the Los Angeles BioMed Research Institute and the University of Washington successfully completed a 28-day trial of a male birth control pill that is designed to restrict sperm production. Although the pill has not been published in a peer-reviewed journal and has yet to receive FDA approval, it may be the first step towards male hormonal contraception.
Rowan T. Chlebowski, MD, PhD, of the Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, discusses study findings from nearly 2 decades of data, which showed a 21% reduction in deaths from breast cancer among postmenopausal women who adhered to a low-fat diet (Abstract 520).
Research conducted at MSK and elsewhere has firmly established the link between excess fat and breast cancer. A major new study presented at ASCO provides the first randomized clinical trial evidence that diet can reduce postmenopausal women’s risk of dying from breast cancer.
A balanced, low-fat diet significantly lowers the risk of dying from breast cancer in postmenopausal women, according to new long-term data from the Women’s Health Initiative (WHI) Dietary Modification trial.
Local schools celebrate blue ribbon week, there is an urgent need of Type O blood and Marissa Lenon who is the organizer for the Hot Ballroom Dancesport Challenge will talk about the event taking place this Sunday at the Torrance Marriott.
"We are not a nation of white men," LA BioMed's David Meyer says. Because race and ethnicity sometimes play a role in how people develop diseases or react to medications, it's important in this age of "personalized medicine" to expand research to include people of color, the elderly, poorer communities, and those in the LGBTQ community.
Many women swear by the effectiveness of “the pill.” These hormonal drugs can prevent unwanted pregnancies by stopping ovulation, and thus, fertilization of egg and sperm. This, in turn, could help couples make informed decisions in practicing safe sex and family planning.
LA BioMed, located in Torrance at the Harbor-UCLA Medical Center, is planning a $63-million, 18,000-square-foot life science incubator and has permits to build an additional 250,000 square feet of life sciences space on 15 acres. The vision for LA BioMed, supported by growing resources, is to become one of the nation’s premier destinations for life sciences.
The discovery was made by Nannette Yount, PhD, a consulting scientist at LA BioMed, and Michael Yeaman, PhD, a professor of medicine at the University of California, Los Angeles (UCLA), and chief of the division of molecular medicine at Harbor-UCLA Medical Center, whose role in this study was as senior investigator at LA BioMed.
The opening of the glass-clad, silver framed, cubist-inspired LA BioMed MRL (Medical Research Laboratory) was celebrated Saturday with a ribbon cutting and tour for supporters. LA BioMed (Los Angeles Biomedical Research Institute ) is in Torrance, next to the Harbor-UCLA Medical Center.
On a recent morning in Los Angeles, Michael Medrano dabbed a teaspoon-sized glob of cold gel onto his shoulders. It’s just another part of his routine these days: Brush teeth, apply deodorant, comb hair, dab gel.
[A]fter years of development, a revolutionary male contraceptive pill has passed initial stages of testing, bringing it one step closer to being a real life, viable option for family planning, and not just a fantastical concept.
Team hopes to improve on 85% success of first study. First study to focus on precise controlled protein expressions via bioelectric signaling sequences intended for mature blood vessel, muscle and nerve regeneration.